Evaluation of the Safety and Efficacy of the Medical Device PROXERA PSOMED 30 in the Treatment of Nail Psoriasis: a Sponsored, Interventional, Single-center, Randomized, Single-site, Intrapatient Controlled Study (NAPSI)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Change in Target Nail NAPSI Score From Baseline to Week 24
研究概览
简要总结
The purpose of this interventional clinical study is to evaluate the safety and efficacy of PROXERA PSOMED 30, a topical medical device containing 30% urea, for the treatment of nail psoriasis in adults with nail psoriasis. The primary question the study aims to answer is whether PROXERA PSOMED 30 improves the clinical signs of nail psoriasis more effectively than a control treatment (Vaseline).
Researchers will compare two similar target nails in the same participant, one treated with PROXERA PSOMED 30 and the other with Vaseline, to determine whether the active treatment leads to greater improvement in Nail Psoriasis Severity Index (NAPSI) scores over 24 weeks. The study will also evaluate local tolerability, patient satisfaction, and digital photographs of the treated nails.
Participants will be men or women between the ages of 18 and 65 with nail psoriasis for at least 6 months and a target NAPSI nail score of 3 or higher. A total of 21 participants is expected.
Participants will:
apply PROXERA PSOMED 30 to one target nail and petroleum jelly to the opposite target nail twice daily for 24 weeks; attend follow-up visits at baseline and after 4, 12, and 24 weeks; undergo nail assessments using the NAPSI score; have digital photographs of treated nails; report tolerability, satisfaction, and any adverse events during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an intra-patient controlled study. Participants are informed which target nail receives active treatment and which receives petrolatum control for self-application. The outcome assessor/evaluator is blinded to treatment allocation during study assessments.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Psoriasis
- •Diagnosis of nail psoriasis for at least 6 months (NAPSI ≥ 3)
- •Male or female
- •Age between 18 and 65 years
- •Willingness to participate in the study and signing the informed consent form
排除标准
- •Known hypersensitivity or intolerance to any component of the product.
- •Concomitant therapy with systemic immunomodulatory drugs (e.g., cyclosporine, apremilast), except methotrexate (MTX), the use of which will be compatible with the study.
- •Concomitant therapy with biologic agents such as anti-TNFα, anti-IL17, or anti-IL
- •Concomitant topical therapy with topical steroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations.
- •Pregnant or breastfeeding women
研究组 & 干预措施
Intra-patient PROXERA PSOMED 30 and Petrolatum Control
Single-group, randomized, single-blind, intra-patient controlled study arm. Each participant has two contralateral target nails with comparable nail psoriasis severity selected at baseline. One target nail is randomized to receive PROXERA PSOMED 30 nail cream (30% urea), and the opposite target nail is randomized to receive petrolatum as control. Treatments are self-applied twice daily (morning and evening) for 24 weeks.
干预措施: Device intervention name: PROXERA PSOMED 30 nail cream; Control intervention name: Petrolatum (Device)
结局指标
主要结局
Change in Target Nail NAPSI Score From Baseline to Week 24
时间窗: Baseline and Week 24
The NAPSI score is assessed for two contralateral target nails selected at baseline (a device-treated nail and a control nail treated with Vaseline). Each nail is divided into four quadrants and the nail matrix and nail bed are assessed for psoriasis signs, resulting in a total score ranging from 0 to 8 per nail, with higher scores indicating greater severity. The primary analysis compares the change in the NAPSI score of the target nail from baseline to week 24 between the device-treated nail and the control nail. Assessments are performed at baseline and at weeks 4, 12, and 24.
次要结局
未报告次要终点